Latest DNLI reports update at 2023-11-07: 2023-Q3 ∙ 2022-Q4 ∙ 2022-Q3

Denali Therapeutics DNLI

$ 15.43 3.14%

Denali Therapeutics Financial Statements 2011-2024 | DNLI

Annual Financial Statements Denali Therapeutics

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	3.36 B	3.96 B	7.82 B	2.23 B	1.75 B	354 M	-	-	-	-	-	-
Shares	126 M	122 M	109 M	95.6 M	92.6 M	15 M	-	-	-	-	-	-
Historical Prices	26.8	32.6	71.8	19.8	21.8	22.9	-	-	-	-	-	-
Net Income	-326 M	-291 M	71.1 M	-198 M	-36.2 M	-88.2 M	-86.7 M	-16.8 M	-	-	-	-
Revenue	108 M	48.7 M	336 M	26.7 M	129 M	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-341 M	-296 M	62.7 M	-213 M	-46.4 M	-90.1 M	-87.4 M	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-330 M	-287 M	71.2 M	-205 M	-39 M	-87.1 M	-86 M	-16.6 M	-	-	-	-
Operating Expenses	449 M	344 M	273 M	240 M	176 M	-	-	-	-	-	-	-
General and Administrative Expenses	90.5 M	79.1 M	60.3 M	46.5 M	32.3 M	15.7 M	11.7 M	5.11 M	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Denali Therapeutics

	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	138 M	137 M	137 M	136 M	123 M	123 M	123 M	122 M	122 M	121 M	121 M	121 M	107 M	106 M	102 M	96.1 M	95.9 M	95.5 M	95 M	94.3 M	93.7 M	92.9 M	89.6 M	87.5 M	10.2 M	9.67 M	9.02 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-99.4 M	183 M	-110 M	-	-103 M	-58.8 M	-65.2 M	-	-84.6 M	-60.7 M	-70 M	-	-58.2 M	-58.8 M	-56.8 M	-54 M	-46.3 M	-58.3 M	-39 M	77.5 M	-35.4 M	-54.7 M	-23.7 M	-22.9 M	-21.8 M	-22.1 M	-21.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	1.27 M	294 M	35.1 M	-	3.56 M	52.5 M	42.1 M	-	5.28 M	22.9 M	7.92 M	-	9.39 M	5.85 M	3.6 M	4.67 M	13.6 M	4.2 M	4.2 M	126 M	1.2 M	1.65 M	641 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-114 M	170 M	-121 M	-	-107 M	-61.4 M	-66.5 M	-	-85.6 M	-61.8 M	-71.2 M	-	-60.1 M	-61.3 M	-60 M	-57.8 M	-50.2 M	-62.8 M	-42.5 M	74.7 M	-38 M	-57.4 M	-25.7 M	-23.5 M	-22.3 M	-22.6 M	-21.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-111 M	-	-101 M	-57.3 M	-64.4 M	-	-79.1 M	-57.5 M	-69.1 M	-	-53.7 M	-57 M	-57.9 M	-57.8 M	-44.2 M	-58.7 M	-40.1 M	74.7 M	-32.9 M	-54.7 M	-24.9 M	-23.5 M	-20 M	-21.1 M	-21 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	115 M	124 M	156 M	-	111 M	114 M	109 M	-	90.9 M	84.8 M	79.1 M	-	69.5 M	67.1 M	63.6 M	-	63.8 M	67 M	46.7 M	-	39.2 M	59 M	26.4 M	-	22.3 M	22.6 M	21.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	25.3 M	26.1 M	27.1 M	-	23.3 M	21.2 M	22.5 M	-	19.3 M	19 M	18.9 M	-	15.8 M	14 M	12.6 M	-	11.2 M	15.1 M	9.31 M	-	8.84 M	6.9 M	5.57 M	-	3.77 M	3.56 M	3.27 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency